References

Human genetic determinants of COVID-19 in Brazil: Challenges and future plans

10.1590/1678-4685-gmb-2023-0128 · 2023 · External reference

Exploring the role of immune system and inflammatory cytokines in SARS-CoV-2 induced lung disease: A narrative review

10.3390/biology12020177 · 2023 · External reference

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

10.1101/2021.03.07.21252875 · 2021 · External reference

Comorbidities, multimorbidity and COVID-19

10.1038/s41591-022-02156-9 · 2023 · External reference

Risk and protective factors for COVID-19 morbidity, severity, and mortality

10.1007/s12016-022-08921-5 · 2023 · External reference

A global Effort to define the human genetics of protective immunity to SARS-CoV-2 infection

10.1016/j.cell.2020.05.016 · 2020 · External reference

Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee

10.70962/jhi.20250003 · 2025 · External reference

Toward a monogenic architecture of human infections: From 1996 to 2026

10.70962/jhi.20260027 · 2026 · External reference

Human immunity

10.70962/jhi.20250001 · 2025 · External reference

Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs

10.1172/jci166283 · 2023 · External reference

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

10.1126/science.abd4570 · 2020 · External reference

The seven enigmas of SARS-CoV-2: From the past to the future

10.70962/jhi.20250149 · 2025 · External reference

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

10.1126/science.abd4585 · 2020 · External reference

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

10.1111/imcb.12495 · 2021 · External reference

Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies

10.1007/s10875-022-01252-2 · 2022 · External reference

Auto-antibodies against type I IFNs in >10% of critically ill COVID-19 patients: A prospective multicentre study

10.1186/s13613-022-01095-5 · 2022 · External reference

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

10.1084/jem.20210554 · 2021 · External reference

Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease

10.1371/journal.pbio.3001709 · 2022 · External reference

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

10.1126/scitranslmed.abj7521 · 2022 · External reference

New-onset IgG autoantibodies in hospitalized patients with COVID-19

10.1038/s41467-021-25509-3 · 2021 · External reference

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital

10.1007/s10875-021-01203-3 · 2022 · External reference

Autoantibodies neutralizing type I INFs may Be associated with efficacy of tocilizumab in COVID-19 pneumonia

10.1007/s10875-022-01295-5 · 2022 · External reference

Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries

10.1038/s41551-022-00925-y · 2022 · External reference

Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19

10.1007/s10875-022-01308-3 · 2022 · External reference

Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity

10.1002/eji.202249824 · 2022 · External reference

Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients

10.1002/cti2.1327 · 2021 · External reference

Examination of autoantibodies to type I interferon in patients suffering from long COVID

10.1002/jmv.29089 · 2023 · External reference

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients

10.1007/s00134-021-06392-4 · 2021 · External reference

Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization

10.1007/s10875-022-01325-2 · 2022 · External reference

Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis

10.1016/j.jaci.2021.03.034 · 2021 · External reference

Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α

10.1136/ard-2022-222549 · 2022 · External reference

Anti-interferon alpha autoantibodies and their significance in COVID-19

10.15789/2220-7619-aaa-1789 · 2022 · External reference

Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia

10.1007/s10875-023-01512-9 · 2023 · External reference

Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons

10.3390/v13122553 · 2021 · External reference

Increased presence of antibodies against type I interferons and human Endogenous Retrovirus W in intensive care unit COVID-19 patients

10.1128/spectrum.01280-22 · 2022 · External reference

Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in barcelona

10.1007/s10875-021-01136-x · 2021 · External reference

A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients

10.1186/s12964-022-00903-6 · 2022 · External reference

Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain

10.1007/s10875-021-01036-0 · 2021 · External reference

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

10.1126/scitranslmed.abh2624 · 2021 · External reference

Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia

10.1089/jir.2023.0003 · 2023 · External reference

Diverse functional autoantibodies in patients with COVID-19

10.1038/s41586-021-03631-y · 2021 · External reference

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

10.1016/j.cell.2021.07.023 · 2021 · External reference

COVID-19 convalescent plasma composition and immunological effects in severe patients

10.1016/j.jaut.2021.102598 · 2021 · External reference

Multiple early factors anticipate post-acute COVID-19 sequelae

10.1016/j.cell.2022.01.014 · 2022 · External reference

Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons

10.1038/s41598-023-43675-w · 2023 · External reference

High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19

10.1016/j.clim.2022.109068 · 2022 · External reference

Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity

10.1038/s41467-022-34895-1 · 2022 · External reference

Suppression of type I interferon signaling in myeloid cells by autoantibodies in severe COVID-19 patients

10.1007/s10875-024-01708-7 · 2024 · External reference

Similar kinetics of pulmonary SARS-CoV-2 load in intensive care unit patients with COVID-19 pneumonia with or without autoantibodies neutralizing type I interferons

10.1007/s10875-024-01839-x · 2025 · External reference

Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19

10.1016/j.jaci.2022.09.005 · 2022 · External reference

Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients

10.1016/j.clim.2025.110491 · 2025 · External reference

COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity

10.1002/jmv.28134 · 2023 · External reference

Prevalence of neutralizing autoantibodies against type I interferon in a multicenter cohort of severe or critical COVID-19 cases in shanghai

10.1007/s10875-024-01683-z · 2024 · External reference

Chest computed tomography characteristics of critically ill COVID-19 patients with auto-antibodies against type I interferons

10.1007/s10875-023-01606-4 · 2024 · External reference

Evaluation of genetic or cellular impairments in type I IFN immunity in a cohort of young adults with critical COVID-19

10.1007/s10875-023-01641-1 · 2024 · External reference

Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa

10.1016/j.clim.2024.110323 · 2024 · External reference

Distinct circulating autoantibodies are associated with COVID-19 hospitalization and SARS-CoV-2 neutralization activity

10.1038/s44298-025-00149-2 · 2025 · External reference

The role of anti-interferon-α autoantibodies in severe COVID-19: Implications for vaccination prioritization

10.3390/vaccines13070742 · 2025 · External reference

Discriminating promiscuous from target-specific autoantibodies in COVID-19

10.1002/eji.202250210 · 2023 · External reference

High anti-interferon-alpha autoantibody levels in severe/critical COVID-19 patients from Peru

10.1089/jir.2023.0087 · 2023 · External reference

Fatal H5N1 avian influenza pneumonia associated with autoantibodies neutralizing type I interferons

10.70962/cis2026abstract.57 · 2026 · External reference

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts

10.70962/jhi.20250189 · 2026 · External reference

Autoantibodies neutralizing type 1 interferons in two cohorts of people with HIV

10.70962/jhi.20250179 · 2026 · External reference

Human autoantibodies neutralizing type I IFNs: From 1981 to 2023

10.1111/imr.13304 · 2024 · External reference

Autoantibodies neutralizing type I IFNs are present in ∼ 4% of uninfected individuals over 70 years old and account for ∼ 20% of COVID-19 deaths

10.1126/sciimmunol.abl4340 · 2021 · External reference

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

10.1073/pnas.2200413119 · 2022 · External reference

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

10.1126/sciimmunol.abp8966 · 2023 · External reference

Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination

10.1084/jem.20220258 · 2023 · External reference

Mild COVID-19 in an APECED patient with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and high titer of type 1 IFN-abs: A case report

10.3390/pathogens12030403 · 2023 · External reference

Diagnosis of APS-1 in two siblings following life-threatening COVID-19 pneumonia

10.1007/s10875-022-01245-1 · 2022 · External reference

Prevalence and association of type I IFN autoantibodies with clinical outcomes in critically ill Brazilian COVID-19 patients

10.70962/jhi.20250031 · 2025 · External reference

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

10.1084/jem.20202486 · 2021 · External reference

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

10.1084/jem.20220514 · 2022 · External reference

Interfering with interferons: A critical mechanism for critical COVID-19 pneumonia

10.1146/annurev-immunol-101921-050835 · 2023 · External reference

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

10.1186/s13073-023-01173-8 · 2023 · External reference

Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19

10.1007/s10875-021-01168-3 · 2022 · External reference

Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening

10.1016/j.hrtlng.2024.03.005 · 2024 · External reference

Low lymphocytes and IFN-neutralizing autoantibodies as biomarkers of COVID-19 mortality

10.1007/s10875-022-01241-5 · 2022 · External reference

Longitudinal Single-Cell Epitope and RNA-Sequencing Reveals the Immunological Impact of Type 1 Interferon Autoantibodies in Critical COVID-19

10.1101/2021.03.09.434529 · 2021 · External reference

Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma

10.1007/s10875-021-01060-0 · 2021 · External reference

IFN-α2 autoantibody screening and functional evaluation in viral and bacterial infections

10.1093/jalm/jfae080 · 2024 · External reference

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

10.1084/jem.20231353 · 2024 · External reference

More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients

10.3389/fimmu.2023.1250214 · 2023 · External reference

Transient increase of pre-existing anti-IFN-α2 antibodies induced by SARS-CoV-2 infection

10.1007/s10875-022-01235-3 · 2022 · External reference

Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1

10.1172/jci150867 · 2021 · External reference

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial

10.1016/s2213-2600(20)30511-7 · 2021 · External reference

Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β

10.1007/s10875-021-01068-6 · 2021 · External reference

Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients

10.1093/cei/uxaf074 · 2026 · External reference

Admixture’s impact on Brazilian population evolution and health

10.1126/science.adl3564 · 2025 · External reference

Autoantibodies against type I interferons are a prominent feature in SARS-CoV-2 fatal disease and hospitalization

10.1093/infdis/jiaf514 · 2025 · External reference

10.22491/hcpa-biobanco-amostras

10.22491/hcpa-biobanco-amostras · 2020 · External reference